Free Trial
NASDAQ:ZLAB

Zai Lab (ZLAB) Stock Price, News & Analysis

Zai Lab logo
$34.56 +0.48 (+1.40%)
As of 09:49 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Zai Lab Stock (NASDAQ:ZLAB)

Key Stats

Today's Range
$34.60
$34.60
50-Day Range
$30.29
$43.03
52-Week Range
$16.01
$44.34
Volume
9,124 shs
Average Volume
999,693 shs
Market Capitalization
$3.84 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$54.28
Consensus Rating
Moderate Buy

Company Overview

Zai Lab Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
51st Percentile Overall Score

ZLAB MarketRank™: 

Zai Lab scored higher than 51% of companies evaluated by MarketBeat, and ranked 562nd out of 921 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Zai Lab has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Zai Lab has only been the subject of 1 research reports in the past 90 days.

  • Read more about Zai Lab's stock forecast and price target.
  • Earnings Growth

    Earnings for Zai Lab are expected to grow in the coming year, from ($2.58) to ($1.74) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Zai Lab is -13.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Zai Lab is -13.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Zai Lab has a P/B Ratio of 4.44. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    3.58% of the outstanding shares of Zai Lab have been sold short.
  • Short Interest Ratio / Days to Cover

    Zai Lab has a short interest ratio ("days to cover") of 4.2.
  • Change versus previous month

    Short interest in Zai Lab has recently increased by 7,956.68%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Zai Lab does not currently pay a dividend.

  • Dividend Growth

    Zai Lab does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    3.58% of the outstanding shares of Zai Lab have been sold short.
  • Short Interest Ratio / Days to Cover

    Zai Lab has a short interest ratio ("days to cover") of 4.2.
  • Change versus previous month

    Short interest in Zai Lab has recently increased by 7,956.68%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Zai Lab has a news sentiment score of 0.78. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.39 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 14 news articles for Zai Lab this week, compared to 6 articles on an average week.
  • Search Interest

    Only 3 people have searched for ZLAB on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.
  • MarketBeat Follows

    2 people have added Zai Lab to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Zai Lab insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,959,535.00 in company stock.

  • Percentage Held by Insiders

    Only 4.96% of the stock of Zai Lab is held by insiders.

  • Percentage Held by Institutions

    41.65% of the stock of Zai Lab is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Zai Lab's insider trading history.
Receive ZLAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zai Lab and its competitors with MarketBeat's FREE daily newsletter.

ZLAB Stock News Headlines

Zai Lab Limited (ZLAB) Q2 2025 Earnings Call Transcript
Zai Lab reports Q2 EPS (4c), consensus (42c)
HIDDEN IN THE BOOK OF GENESIS…
“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 trillion vault of untapped American wealth. Former CIA advisor Jim Rickards calls it the “Old Testament Wealth Code” — and says it could transform your financial future. He’s revealing everything in a new presentation.
Zai Lab (ZLAB) Projected to Post Earnings on Thursday
See More Headlines

ZLAB Stock Analysis - Frequently Asked Questions

Zai Lab's stock was trading at $26.19 on January 1st, 2025. Since then, ZLAB shares have increased by 30.1% and is now trading at $34.08.

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) released its quarterly earnings data on Thursday, May, 8th. The company reported ($0.45) EPS for the quarter, beating the consensus estimate of ($0.50) by $0.05. The firm earned $106.49 million during the quarter, compared to the consensus estimate of $118.40 million. Zai Lab had a negative trailing twelve-month return on equity of 33.35% and a negative net margin of 60.26%.
Read the conference call transcript
.

Zai Lab (ZLAB) raised $100 million in an initial public offering on Wednesday, September 20th 2017. The company issued 5,900,000 shares at $16.00-$18.00 per share. J.P. Morgan, Citigroup and Leerink Partners acted as the underwriters for the IPO.

Shares of ZLAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Zai Lab investors own include NVIDIA (NVDA), Tesla (TSLA), Intel (INTC), Meta Platforms (META), Advanced Micro Devices (AMD), Baidu (BIDU) and Home Depot (HD).

Company Calendar

Last Earnings
8/07/2025
Today
8/08/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ZLAB
CIK
1704292
Employees
1,869
Year Founded
N/A

Price Target and Rating

High Price Target
$75.00
Low Price Target
$36.10
Potential Upside/Downside
+59.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
5 Analysts

Profitability

EPS (Trailing Twelve Months)
($2.49)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$257.10 million
Net Margins
-60.26%
Pretax Margin
-60.26%
Return on Equity
-33.35%
Return on Assets
-23.28%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
3.26
Quick Ratio
3.09

Sales & Book Value

Annual Sales
$398.99 million
Price / Sales
9.49
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$7.68 per share
Price / Book
4.44

Miscellaneous

Outstanding Shares
111,080,000
Free Float
105,569,000
Market Cap
$3.79 billion
Optionable
Optionable
Beta
1.03

Social Links

Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:ZLAB) was last updated on 8/8/2025 by MarketBeat.com Staff
From Our Partners